Next report date
Report period
Q1 2024
EPS estimate
−0.25USD
Revenue estimate
13.96 MUSD
−55.19 MUSD
57.42 MUSD
43.68 M
Om Theravance Biopharma, Inc.
Sektor
Bransch
VD
Rick E. Winningham
Webbplats
Huvudkvarter
South San
Employees (FY)
99
Grundat
2013
ISIN
KYG8807B1068
FIGI
BBG004HK6YX1
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
